Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Pfizer Deal Pushes Carlyle-Backed Drug Developer PPD to Record

Published 08/03/2020, 11:44 AM
Updated 08/03/2020, 11:45 AM
© Reuters.

By Christiana Sciaudone

Investing.com --   PPD (NASDAQ:PPD) Inc. jumped 7% to an all-time high after signing a deal with pharmaceutical giant Pfizer (NYSE:PFE).

The drug developer said it inked a three-year agreement with Pfizer to provide development services to advance Pfizer’s portfolio. Pfizer has the right to extend the term for additional two-year periods. Financial details of the agreement were not disclosed.

The agreement builds on the companies’ existing relationship.

PPD, which went public in February, is a global contract research organization providing drug development, laboratory and lifecycle management services. The company reports quarterly earnings on Tuesday..

PPD has been owned by private equity firms Carlyle Group (NASDAQ:CG) and Hellman & Friedman since 2011 after the pair took the company private in a $3.9 billion leveraged buyout, according to Reuters. 

 

 

 



Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.